Blab AI
Aidoc Receives FDA Breakthrough Device Designation for Chest X-ray AI Tool
Aidoc Medical, the Israeli company that builds computer‑aided triage systems for radiology, has been granted a Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA) for its new AI product, First Read. The designation, announced on 25 June 2026, applies to an algorithm that analyzes chest radiographs and produces draft radiology report text.
First Read is built on the same underlying architecture that powers Aidoc’s FDA‑cleared abdominal CT triage application, Triage. The system is designed to shorten the time radiologists spend preparing reports while keeping the final interpretation and approval in human hands. The FDA’s Breakthrough Device Designation is reserved for technologies that represent a significant advance in diagnosing serious conditions and that address unmet clinical needs. The program is intended to accelerate the availability of such innovations.
The designation marks Aidoc’s second Breakthrough Device award in less than a year. In September 2025 the company received the same status for Care Triage, a multi‑condition AI triage solution for abdominal CT scans. According to Aidoc, its platform is already deployed in nearly 2,000 hospitals worldwide and has processed more than 120 million patient cases.
Chest radiographs are the most common imaging study performed in hospitals and emergency departments. They are used to detect a wide range of conditions, from pneumonia and pulmonary embolism to fractures and foreign bodies. The volume of studies and the need for rapid interpretation create a demand for tools that can assist radiologists without compromising diagnostic accuracy.
Aidoc’s First Read is intended to address that demand by automatically generating a preliminary report that highlights abnormal findings and suggests a structured narrative. Radiologists can then review, edit, and sign off on the final report. The company’s statement notes that the system is designed to preserve radiologist oversight and final approval, a key requirement for FDA clearance of AI‑assisted diagnostic tools.
The FDA’s announcement cites the Breakthrough Device Designation program’s criteria, which include evidence that the device offers a substantial improvement over existing options and that it addresses a serious or life‑threatening condition. While the FDA has not released detailed performance data for First Read, the company’s prior approvals for Triage and Care Triage provide a track record of regulatory compliance.
First Read’s underlying architecture is based on a foundation model that has been trained on large volumes of imaging data. Aidoc’s platform has previously been used to triage 14 different abdominal CT indications in a single workflow, and the company has expanded the approach to chest X‑ray studies.
The Breakthrough Device Designation does not equate to FDA clearance for commercial sale. The FDA has indicated that First Read is currently under review and that a 510(k) submission is pending. The designation is meant to expedite the review process and to provide the company with additional support from the FDA.
Industry observers note that the designation reflects a broader trend of AI tools moving from single‑condition solutions to multi‑condition, foundation‑model‑based systems. The ability to generate structured report text could streamline workflow in high‑volume settings and reduce the time to diagnosis.
Aidoc’s platform has been deployed in a variety of institutions, including Montefiore Nyack Hospital, LifeBridge Health, Yale New Haven Hospital, and Cedars‑Sinai Medical Center, among others. The company has also reported that its AI solutions are used in more than 900 hospitals and imaging centers worldwide.
In the coming months, Aidoc is expected to submit the final regulatory documentation for First Read and to begin clinical trials that will evaluate the system’s impact on reporting times and diagnostic accuracy. The company has indicated that it will continue to expand the scope of its foundation model to cover additional imaging modalities.
The FDA’s Breakthrough Device Designation for First Read underscores the growing acceptance of AI‑assisted diagnostic tools in radiology and highlights the potential for foundation models to improve efficiency and consistency across imaging studies.
The current status of First Read is that it remains under FDA review, with a 510(k) submission pending. No commercial availability in the United States has been announced.
The designation is a milestone for Aidoc and for the broader AI‑in‑healthcare ecosystem, as it demonstrates the regulatory pathway for advanced AI systems that can assist radiologists in interpreting the most common imaging study in medicine.
First Read is built on the same underlying architecture that powers Aidoc’s FDA‑cleared abdominal CT triage application, Triage. The system is designed to shorten the time radiologists spend preparing reports while keeping the final interpretation and approval in human hands. The FDA’s Breakthrough Device Designation is reserved for technologies that represent a significant advance in diagnosing serious conditions and that address unmet clinical needs. The program is intended to accelerate the availability of such innovations.
The designation marks Aidoc’s second Breakthrough Device award in less than a year. In September 2025 the company received the same status for Care Triage, a multi‑condition AI triage solution for abdominal CT scans. According to Aidoc, its platform is already deployed in nearly 2,000 hospitals worldwide and has processed more than 120 million patient cases.
Chest radiographs are the most common imaging study performed in hospitals and emergency departments. They are used to detect a wide range of conditions, from pneumonia and pulmonary embolism to fractures and foreign bodies. The volume of studies and the need for rapid interpretation create a demand for tools that can assist radiologists without compromising diagnostic accuracy.
Aidoc’s First Read is intended to address that demand by automatically generating a preliminary report that highlights abnormal findings and suggests a structured narrative. Radiologists can then review, edit, and sign off on the final report. The company’s statement notes that the system is designed to preserve radiologist oversight and final approval, a key requirement for FDA clearance of AI‑assisted diagnostic tools.
The FDA’s announcement cites the Breakthrough Device Designation program’s criteria, which include evidence that the device offers a substantial improvement over existing options and that it addresses a serious or life‑threatening condition. While the FDA has not released detailed performance data for First Read, the company’s prior approvals for Triage and Care Triage provide a track record of regulatory compliance.
First Read’s underlying architecture is based on a foundation model that has been trained on large volumes of imaging data. Aidoc’s platform has previously been used to triage 14 different abdominal CT indications in a single workflow, and the company has expanded the approach to chest X‑ray studies.
The Breakthrough Device Designation does not equate to FDA clearance for commercial sale. The FDA has indicated that First Read is currently under review and that a 510(k) submission is pending. The designation is meant to expedite the review process and to provide the company with additional support from the FDA.
Industry observers note that the designation reflects a broader trend of AI tools moving from single‑condition solutions to multi‑condition, foundation‑model‑based systems. The ability to generate structured report text could streamline workflow in high‑volume settings and reduce the time to diagnosis.
Aidoc’s platform has been deployed in a variety of institutions, including Montefiore Nyack Hospital, LifeBridge Health, Yale New Haven Hospital, and Cedars‑Sinai Medical Center, among others. The company has also reported that its AI solutions are used in more than 900 hospitals and imaging centers worldwide.
In the coming months, Aidoc is expected to submit the final regulatory documentation for First Read and to begin clinical trials that will evaluate the system’s impact on reporting times and diagnostic accuracy. The company has indicated that it will continue to expand the scope of its foundation model to cover additional imaging modalities.
The FDA’s Breakthrough Device Designation for First Read underscores the growing acceptance of AI‑assisted diagnostic tools in radiology and highlights the potential for foundation models to improve efficiency and consistency across imaging studies.
The current status of First Read is that it remains under FDA review, with a 510(k) submission pending. No commercial availability in the United States has been announced.
The designation is a milestone for Aidoc and for the broader AI‑in‑healthcare ecosystem, as it demonstrates the regulatory pathway for advanced AI systems that can assist radiologists in interpreting the most common imaging study in medicine.
